125 related articles for article (PubMed ID: 15866693)
1. Anti-TNF-alpha therapy for acute rejection in intestinal transplantation.
Pascher A; Klupp J; Langrehr JM; Neuhaus P
Transplant Proc; 2005 Apr; 37(3):1635-6. PubMed ID: 15866693
[TBL] [Abstract][Full Text] [Related]
2. Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantation.
Pascher A; Radke C; Dignass A; Schulz RJ; Veltzke-Schlieker W; Adler A; Sauer IM; Platz K; Klupp J; Volk HD; Neuhaus P; Mueller AR
Transplantation; 2003 Aug; 76(3):615-8. PubMed ID: 12923454
[TBL] [Abstract][Full Text] [Related]
3. Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation.
Tzakis AG; Kato T; Nishida S; Levi DM; Madariaga JR; Nery JR; Mittal N; Regev A; Cantwell P; Gyamfi A; Weppler D; Miller J; Tryphonopoulos P; Ruiz P
Transplantation; 2003 Apr; 75(8):1227-31. PubMed ID: 12717207
[TBL] [Abstract][Full Text] [Related]
4. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.
Cuppoletti A; Perez-Villa F; Vallejos I; Roig E
Transplant Proc; 2005 Nov; 37(9):4036-8. PubMed ID: 16386620
[TBL] [Abstract][Full Text] [Related]
5. Evolutionary experience with immunosuppression in pediatric intestinal transplantation.
Bond GJ; Mazariegos GV; Sindhi R; Abu-Elmagd KM; Reyes J
J Pediatr Surg; 2005 Jan; 40(1):274-9; discussion 279-80. PubMed ID: 15868597
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation.
Tzakis AG; Kato T; Nishida S; Levi DM; Tryphonopoulos P; Madariaga JR; De Faria W; Nery JR; Regev A; Vianna R; Miller J; Esquenazi V; Weppler D; Ruiz P
Transplantation; 2003 May; 75(9):1512-7. PubMed ID: 12792506
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor alpha inhibitors as immunomodulatory antirejection agents after intestinal transplantation.
Gerlach UA; Koch M; Müller HP; Veltzke-Schlieker W; Neuhaus P; Pascher A
Am J Transplant; 2011 May; 11(5):1041-50. PubMed ID: 21521472
[TBL] [Abstract][Full Text] [Related]
8. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppression following intestinal transplantation.
Mueller AR; Pascher A; Platz KP; Braun F; Fändrich F; Rayes N; Seehofer D; Radtke C; Neuhaus P; Kremer B
Transplant Proc; 2004 Mar; 36(2):325-8. PubMed ID: 15050147
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation.
Shennib H; Massard G; Reynaud M; Noirclerc M
J Heart Lung Transplant; 1994; 13(3):514-9. PubMed ID: 8061029
[TBL] [Abstract][Full Text] [Related]
11. Three-year experience in clinical intestinal transplantation.
Masetti M; Cautero N; Lauro A; Di Benedetto F; Begliomini B; Siniscalchi A; Pironi L; Miglioli M; Bagni A; Pinna AD
Transplant Proc; 2004 Mar; 36(2):309-11. PubMed ID: 15050141
[TBL] [Abstract][Full Text] [Related]
12. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus rescue therapy for corticosteroid-resistant and polyclonal antibody-resistant kidney allograft rejections.
Naderi GH; Mehraban D; Ganji MR; Yahyazadeh SR; Latif AH
Urol J; 2009; 6(1):31-4. PubMed ID: 19241339
[TBL] [Abstract][Full Text] [Related]
14. Antimouse antibody response after OKT3 administration for steroid resistant rejection.
Kaiser BA; Palmer JA; Dunn SP; Mochon MA; Bartosh SM; Schulman SL; Polinsky MS; Baluarte HJ
Child Nephrol Urol; 1991; 11(4):190-2. PubMed ID: 1777898
[TBL] [Abstract][Full Text] [Related]
15. Rejection episodes and 3-year graft survival under sirolimus and tacrolimus treatment after adult intestinal transplantation.
Lauro A; Dazzi A; Ercolani G; Zanfi C; Golfieri L; Amaduzzi A; Cucchetti A; La Barba G; Grazi GL; D'Errico A; Vivarelli M; Cescon M; Varotti G; Del Gaudio M; Ravaioli M; Di Simone M; Faenza S; Pironi L; Pinna AD
Transplant Proc; 2007 Jun; 39(5):1629-31. PubMed ID: 17580204
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD3 and -CD4 monoclonal antibody in the treatment of steroid-resistant renal allograft rejection.
Wang XH; Xie T
Chin Med J (Engl); 1993 Nov; 106(11):821-4. PubMed ID: 8143493
[TBL] [Abstract][Full Text] [Related]
17. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss.
Bahra M; Neumann UP; Jacob D; Langrehr JM; Neuhaus P
Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of muromonab-CD3 (OKT3) versus daclizumab (Zenapax) in cardiac transplantation at our center.
Campos A; Lage E; Hinojosa R; Ordóñez A; Cisneros JM; Cabezón S; Gómez S; Aguilera A; Arana E; Cayuela A
Transplant Proc; 2005 Apr; 37(3):1548-9. PubMed ID: 15866669
[TBL] [Abstract][Full Text] [Related]
19. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation.
Garcia M; Weppler D; Mittal N; Nishida S; Kato T; Tzakis A; Ruiz P
Transplant Proc; 2004 Mar; 36(2):323-4. PubMed ID: 15050146
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of tacrolimus and infliximab reduces inflammatory response and dysmotility in experimental small bowel transplantation in rats.
Pech T; Fujishiro J; Finger T; Ohsawa I; Praktiknjo M; Abu-Elmagd K; von Websky M; Overhaus M; Kalff JC; Schaefer N
Transplantation; 2012 Feb; 93(3):249-56. PubMed ID: 22167049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
